Sareum Holdings reports delays in auto-immune research, but encouraging results
Progress on treatment for COVID 19 lung inflammation is still on schedule however, says Sareum in its latest trading update. Continue reading Sareum Holdings reports delays in auto-immune research, but encouraging results at The Armchair Trader.
Sareum Holdings reports delays in auto-immune research, but encouraging results
Progress on treatment for COVID 19 lung inflammation is still on schedule however, says Sareum in its latest trading update. Continue reading Sareum Holdings reports delays in auto-immune research, but encouraging results at The Armchair Trader.